151751-Najiba-Chargi

251 Systemic therapy: skeletal muscle mass and anti-cancer drug toxicity REFERENCES 1. Siddiqui JA, Pothuraju R, Jain M, Batra SK, Nasser MW. Advances in cancer ca - chexia: Intersection between affected organs, mediators, and pharmacologi- cal interventions. Biochim Biophys Acta - Rev Cancer . 2020;1873(2). doi:10.1016/j. bbcan.2020.188359 2. Wiegert EVM, de Oliveira LC, Calixto-Lima L, et al. Association between LowMuscle Mass and Survival in Incurable Cancer Patients: A Systematic Review. Nutrition . 2020;72. doi:10.1016/j.nut.2019.110695 3. Go S Il, Park MJ, Song HN, et al. Sarcopenia and inflammation are independent pre- dictors of survival in male patients newly diagnosed with small cell lung cancer. Sup- port Care Cancer . 2016;24(5):2075-2084. doi:10.1007/s00520-015-2997-x 4. Jung HW, Kim JW, Kim JY, et al. Effect of muscle mass on toxicity and survival in pa- tients with colon cancer undergoing adju- vant chemotherapy. Support Care Cancer . 2015;23(3):687-694. doi:10.1007/s00520- 014-2418-6 5. Barret M, Antoun S, Dalban C, et al. Sarco - penia is linked to treatment toxicity in pa- tients with metastatic colorectal cancer. Nutr Cancer . 2014;66(4):583-589. doi:10.10 80/01635581.2014.894103 6. Prado CMM, Baracos VE, McCargar LJ, et al. Sarcopenia as a Determinant of Che - motherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment. Clin Cancer Res . 2009;15(8):2920-2926. doi:10.1158/1078-0432.CCR-08-2242 7. Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting tox- icities in renal cancer patients. Br J Cancer . 2013;108(5):1034-1041. doi:10.1038/ bjc.2013.58 8. Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. 2017. doi:10.1016/j.oraloncol - ogy.2017.05.012 9. Raafi Ali1 VEBMBSLBSREA, Caroline Mol- levi4 & Pierre Senesse2 5. Lean body mass as an independent determinant of dose-lim- iting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med . 2016;5(4):607-616. doi:10.1002/cam4.621 10. Ansari E, Chargi N, van Gemert JTM, et al. Low skeletal muscle mass is a strong pre- dictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap. Oral Oncol . 2020;101. doi:10.1016/j.oraloncology.2019.104530 11. Hilmi M, Jouinot A, Burns R, et al. Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology? 2018. doi:10.1016/j. pharmthera.2018.12.003 12. Prado CMM, Birdsell LA, Baracos VE. The emerging role of computerized tomogra- phy in assessing cancer cachexia. Curr Opin Support Palliat Care . 2009;3(4):269-275. doi:10.1097/SPC.0b013e328331124a 13. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdom- inal cross-sectional image. J Appl Physiol . 2004;97(6):2333-2338. doi:10.1152/jap - plphysiol.00744.2004 14. Chargi N, Ansari E, Huiskamp LFJ, Bol G, de Bree R. Agreement between skeletal muscle mass measurements using computed to- mography imaging andmagnetic resonance imaging in head and neck cancer patients. Oral Oncol . 2019;99:104341. doi:10.1016/j. oraloncology.2019.06.022 13